English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Colorectal cancer is one of the most common malignancies and a leading cause of death. It is estimated that during 2006 there were 412,900 new cases of colorectal carcinoma diagnosed in Europe and 207,500 deaths. The five-year survival of patients with metastatic disease is less than 7%. Hepatic metastases are present in 15–25% of patients at the time of diagnosis of colorectal cancer, and another 15–20% will develop metachronous liver metastases within five years following resection of the primary tumor. Progression of liver disease also leads to significant clinical morbidity, which is frequently correlated with overall survival. The earlier identification of liver metastases should improve the management and survival of patients with colorectal cancer.

The Emerging Synergy between Radioembolization, Systemic Chemotherapy, and Liver Surgery in Metastatic Colorectal Cancer